Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
Why the verdict in New Hampshire's trial over youth center abuse is being disputedChinese paddlers stunned at WTT 2024 Saudi SmashRICHARD LITTLEJOHN: Welcome to Balti Towers, Basil Fawlty's new asylum hotel...Weddings should be subsidised by the government for lowHospital knife rampage leaves more than ten people dead or wounded in ChinaSoccer fans now have a day to celebrate the world's most popular sportKenvue, Crocs rise; Disney, Teradata fall, Tuesday, 5/7/2024Star guard Kadary Richmond transfers to St. John's from Big East rival Seton HallClosing prices for crude oil, gold and other commoditiesLouisiana lawmakers reject adding exceptions of rape and incest to abortion ban